Calithera Biosciences 2016 Pipeline Presentation

Calithera Biosciences is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting tumor and immune cell metabolism. The company's lead program, CB-839 (glutaminase inhibitor), is entering Phase 2 trials with a clinical collaboration with Bristol Myers Squibb/Opdivo, while CB-1158 (arginase inhibitor) is in Phase 1 development in partnership with Incyte.